Published in J Virol on September 08, 2010
Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol (2013) 0.91
Blood Groups in Infection and Host Susceptibility. Clin Microbiol Rev (2015) 0.88
Role of capsid proteins in parvoviruses infection. Virol J (2015) 0.86
Human Parvoviruses. Clin Microbiol Rev (2017) 0.84
Characterization of the early steps of human parvovirus B19 infection. J Virol (2012) 0.81
The Receptor-Binding Domain in the VP1u Region of Parvovirus B19. Viruses (2016) 0.76
The VP1u Receptor Restricts Parvovirus B19 Uptake to Permissive Erythroid Cells. Viruses (2016) 0.75
Glycosphingolipid GM3 is Indispensable for Dengue Virus Genome Replication. Int J Biol Sci (2016) 0.75
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell (2001) 3.97
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc Natl Acad Sci U S A (2005) 1.85
A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol (2005) 1.79
Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol (1987) 1.77
Clinical aspects of parvovirus B19 infection. J Intern Med (2006) 1.70
Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly. Virology (1999) 1.60
The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. J Virol (2002) 1.52
Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med (1994) 1.45
Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood (2003) 1.45
Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol (1993) 1.45
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol (2007) 1.40
The structure of human parvovirus B19 at 8 A resolution. Virology (1994) 1.38
Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood (2005) 1.29
Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A (1996) 1.29
Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol (2001) 1.17
The parvovirus capsid odyssey: from the cell surface to the nucleus. Trends Microbiol (2008) 1.15
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice. Virology (2004) 1.15
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol (2002) 1.13
Depletion of virion-associated divalent cations induces parvovirus minute virus of mice to eject its genome in a 3'-to-5' direction from an otherwise intact viral particle. J Virol (2009) 1.03
T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19. J Infect Dis (2001) 1.03
Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol (2006) 1.02
Murine lipid phosphate phosphohydrolase-3 acts as a cell-associated integrin ligand. Biochem Biophys Res Commun (2005) 1.00
Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology (1995) 1.00
Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol (2008) 1.00
The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J Gen Virol (2001) 0.99
Trafficking and propagation of canine adenovirus vectors lacking a known integrin-interacting motif. Hum Gene Ther (2001) 0.97
A murine monoclonal IgM antibody specific for blood group P antigen (globoside) Br J Haematol (1986) 0.93
Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol (2001) 0.92
Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology (2005) 0.92
Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology (2005) 0.86
Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses. Transfusion (2007) 0.84
Role of integrin cross-regulation in parvovirus B19 targeting. Hum Gene Ther (2006) 0.80
Pharmacological activation of guanine nucleotide exchange factors for the small GTPase Rap1 recruits high-affinity beta1 integrins as coreceptors for parvovirus B19: improved ex vivo gene transfer to human erythroid progenitor cells. Hum Gene Ther (2009) 0.78
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice. Virology (2004) 1.15
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol (2002) 1.13
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion (2012) 1.06
Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol (2006) 1.02
Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol (2008) 1.00
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2009) 0.97
Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals (2003) 0.92
Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology (2005) 0.92
Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol (2013) 0.91
Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals (2011) 0.88
Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol (2003) 0.88
Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis (2010) 0.87
Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion (2004) 0.86
Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses. Transfusion (2007) 0.84
Characterization of the early steps of human parvovirus B19 infection. J Virol (2012) 0.81
Prevalence of equine herpesvirus types 2 and 5 in horse populations by using type-specific PCR assays. Vet Res (2002) 0.80
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2011) 0.79
Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol (2005) 0.78
Functional integrity of intravenous immunoglobulin following irradiation with a virucidal dose of gamma radiation. Biologicals (2004) 0.77
Impaired genome encapsidation restricts the in vitro propagation of human parvovirus B19. J Virol Methods (2013) 0.77